SEC Tracker
Get the app
ALMS · XBRL financial data

Alumis financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ALMS's year ends in late December)

In millions of dollarsJun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers———17322*22
Research and development498887*971099883*8285
General and administrative81111*22342016*1923
Total operating expenses569899*11914311798*100151
Operating income (loss)(56)(98)(99)*(102)(141)(115)(96)*(98)(149)
Interest income2————————
Other income (expense)(0)(0)(0)*(0)(0)(0)(0)*0(0)
Income tax expense (benefit)000*—(9)00*—(2)
Net income (loss)(57)(93)(95)*(99)59(111)(93)*(93)(142)
Earnings per share, basic USD per share(23.10)(1.73)—(1.82)0.78(1.06)(0.89)*(0.74)(1.11)
Earnings per share, diluted USD per share(23.10)(1.73)—(1.82)0.77(1.06)(0.89)*(0.74)(1.11)
Weighted average shares, basic millions of shares254—5476104104*125128
Weighted average shares, diluted millions of shares254—5477104104*125128
  • † Share count changed about 22x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ALMS's year ends in late December)

In millions of dollarsJun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents15521317012915265906464
Marketable securities5414811980335312219——
Prepaid and other current assets23542411767
Total current assets225377306226518393318532514
Property and equipment, net222121202019181817
Right-of-use asset131313141818171617
Total assets265413341261611488412672561
Accounts payable96107155101213
Total current liabilities333451608665737176
Lease liability, non-current303029293533323132
Total liabilities65648193126103111105108
Accumulated deficit(471)(564)(659)(758)(698)(809)(902)(995)(1,137)
Total stockholders' equity(439)348260168485385301567452
Total liabilities and equity265413341261611488412672561
  • † Share count changed about 22x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ALMS's year ends in late December)

In millions of dollarsJun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(57)(93)(95)*(99)59(111)(93)*(93)(142)
Stock-based compensation3*7*6*719*10*8*1214*
Depreciation and amortization1*1*1*11*1*1*11*
Net cash from operating activities(52)*(84)*(75)*(80)(106)*(111)*(72)*(87)(82)*
Purchases of property and equipment0*1*0*01*0*0*00*
Net cash from investing activities(33)*(93)*31*39129*24*95*(286)69*
Proceeds from issuing common stock———————3240*
Share repurchases——0*——0*0*——
Net cash from financing activities128*235*0*——0*1*34713*
  • † Share count changed about 22x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Alumis641.7(82)*not reported0.8 quarters 10-QJun 30, 2026
Crescent Biopharma1720(19)*37.1M8.8 quarters 10-QJun 30, 2026
Editas Medicine18212(30)*153.6M7.2 quarters 10-QJun 30, 2026
Omeros2294.1*72.4M— 10-QJun 30, 2026
Palvella Therapeutics188not reported(13)*14.4M19.5 quarters 10-QJun 30, 2026
Lexicon Pharmaceuticals410.7(9.2)*445.0M20.7 quarters 10-QJun 30, 2026
Esperion Therapeutics15680(28)257.4M5.6 quarters 10-QMar 31, 2026
XOMA Royalty86126.112.5M— 10-QMar 31, 2026
4D Molecular Therapeutics703.8(70)*55.2M5.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.